Drugs / ABBV-701
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06895343 | Apr 2025 → Nov 2026 expected | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07697456 | Jul 2026 → Oct 2031 expected | Crohn disease, ulcerative colitis | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07697456 ↗ |
| Route | Subcutaneous | “Subcutaneous” NCT06895343 ↗ |